The approval covers a six-month sustained-release version of Decapeptyl®, an LHRH agonist. Debiopharm and its European marketing partner, Ipsen, confirmed regulatory approval of its prostate cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback